Stockscreener 앱 받기
1.28
5.19%
-0.07
시간 외 거래:
1.08
-0.20
-15.62%
전일 마감가:
$1.35
열려 있는:
$1.31
하루 거래량:
4.41M
Relative Volume:
1.05
시가총액:
$208.61M
수익:
-
순이익/손실:
$-111.13M
주가수익비율:
-0.9697
EPS:
-1.32
순현금흐름:
$-91.53M
1주 성능:
-11.11%
1개월 성능:
-27.68%
6개월 성능:
+184.51%
1년 성능:
-48.80%
1일 변동 폭
$1.25
$1.34
1주일 범위
$1.25
$1.54
52주 변동 폭
$0.36
$4.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
TNYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
1.28 | 220.02M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-10 | 개시 | William Blair | Outperform |
| 2023-11-30 | 개시 | Leerink Partners | Outperform |
| 2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
Tenaya Therapeutics Presents Promising Interim Results from MyPEAK-1 Clinical Trial of TN-201 at AHA Scientific Sessions 2025 - Quiver Quantitative
Tenaya (NASDAQ: TNYA) reports TN-201 interim data: troponin I down 74%, MyBP-C up 14% - Stock Titan
Trend analysis for Tenaya Therapeutics Inc. this weekPortfolio Value Report & Low Drawdown Trading Strategies - newser.com
Tenaya Therapeutics reveals MyPEAK-1 trial data - Traders Union
FDA places clinical hold on Tenaya Therapeutics’ TN-201 trial for hypertrophic cardiomyopathy By Investing.com - Investing.com Australia
FDA places clinical hold on Tenaya Therapeutics’ TN-201 trial for hypertrophic cardiomyopathy - Investing.com India
US FDA places clinical hold on Tenaya gene therapy trial for rare heart disease - Reuters
Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial - Seeking Alpha
Tenaya Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial - TipRanks
US FDA places clinical hold on Tenaya Therapeutics' gene therapy - MarketScreener
Will Tenaya Therapeutics Inc. stock continue dividend increases2025 Volatility Report & AI Powered Market Trend Analysis - newser.com
How resilient is Tenaya Therapeutics Inc. stock in market downturnsEarnings Summary Report & Free Real-Time Market Sentiment Alerts - newser.com
When is the best time to exit Tenaya Therapeutics Inc.Index Update & Free Growth Oriented Trading Recommendations - newser.com
Tenaya Therapeutics Inc. stock chart pattern explained2025 Retail Activity & Low Drawdown Trading Techniques - newser.com
Is Tenaya Therapeutics Inc. stock positioned well for digital economyMarket Rally & Verified Chart Pattern Signals - newser.com
Is Tenaya Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Opening Moves & Pattern Based Trade Signal System - newser.com
Will Tenaya Therapeutics Inc. stock gain from lower inflationWeekly Gains Summary & AI Optimized Trade Strategies - newser.com
Statistical indicators supporting Tenaya Therapeutics Inc.’s strengthTrend Reversal & Trade Opportunity Analysis - newser.com
Tenaya Therapeutics unveils advancements at AHA25 sessions - Traders Union
Tenaya to present interim data on MYBPC3-HCM gene therapy at AHA - Investing.com Nigeria
Can Tenaya Therapeutics Inc. stock rebound after recent weaknessTreasury Yields & Advanced Swing Trade Entry Alerts - newser.com
Will Tenaya Therapeutics Inc. stock attract ESG investorsDividend Hike & Safe Capital Growth Stock Tips - newser.com
What analysts say about Tenaya Therapeutics Inc stockInflation Impact on Stocks & Big Data Market Reports - earlytimes.in
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 - The Manila Times
Tenaya Therapeutics to Present Interim Results from MyPEAK-1 Clinical Trial at AHA 2025 Scientific Sessions - Quiver Quantitative
Tenaya (NASDAQ: TNYA) presents TN-201 MyPEAK-1 interim data in AHA late-breaking session - Stock Titan
Is Tenaya Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Catalysts & Accurate Entry/Exit Alerts - fcp.pa.gov.br
Should you wait for a breakout in Tenaya Therapeutics Inc.Weekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
How to escape a deep drawdown in Tenaya Therapeutics Inc.2025 Key Lessons & Daily Volume Surge Trade Alerts - newser.com
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.44%
0.70%
자본화:
|
볼륨(24시간):